Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in IDH2-Mutant Angioimmunoblastic T-Cell Lymphoma
NCT06756308Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2024; status: active, not recruiting.
02
Drugs
enasidenib
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT06756308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756308.